Concepts (101)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinosarcoma | 1 | 2024 | 108 | 0.880 |
Why?
|
Scedosporium | 1 | 2021 | 10 | 0.790 |
Why?
|
Gallbladder Neoplasms | 1 | 2021 | 191 | 0.640 |
Why?
|
Skin Neoplasms | 8 | 2024 | 5891 | 0.580 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2024 | 2847 | 0.470 |
Why?
|
Hepatitis B Surface Antigens | 2 | 2018 | 294 | 0.270 |
Why?
|
Neoplasm Staging | 1 | 2021 | 11249 | 0.260 |
Why?
|
Collagen Diseases | 1 | 2024 | 39 | 0.240 |
Why?
|
Hamartoma Syndrome, Multiple | 1 | 2024 | 115 | 0.210 |
Why?
|
Hepatitis B | 2 | 2018 | 707 | 0.200 |
Why?
|
Hyphae | 1 | 2021 | 52 | 0.190 |
Why?
|
Chickenpox | 1 | 2022 | 96 | 0.190 |
Why?
|
Scalp | 1 | 2024 | 392 | 0.190 |
Why?
|
Pregnancy Complications, Infectious | 3 | 2018 | 2181 | 0.190 |
Why?
|
Pancytopenia | 1 | 2022 | 102 | 0.190 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2024 | 711 | 0.180 |
Why?
|
Pruritus | 1 | 2024 | 380 | 0.180 |
Why?
|
Lymphoma, Mantle-Cell | 1 | 2023 | 238 | 0.180 |
Why?
|
Infectious Disease Transmission, Vertical | 2 | 2018 | 1359 | 0.180 |
Why?
|
Post-Exposure Prophylaxis | 2 | 2018 | 110 | 0.180 |
Why?
|
Hepatitis B Vaccines | 2 | 2018 | 177 | 0.180 |
Why?
|
Immunohistochemistry | 2 | 2024 | 11139 | 0.180 |
Why?
|
Chile | 1 | 2021 | 258 | 0.170 |
Why?
|
Melanoma | 3 | 2023 | 5740 | 0.170 |
Why?
|
Herpes Zoster | 1 | 2022 | 253 | 0.170 |
Why?
|
Carcinoma, Merkel Cell | 1 | 2023 | 331 | 0.160 |
Why?
|
Republic of Korea | 1 | 2021 | 587 | 0.160 |
Why?
|
PTEN Phosphohydrolase | 1 | 2024 | 1119 | 0.150 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2024 | 4083 | 0.150 |
Why?
|
Antifungal Agents | 1 | 2021 | 761 | 0.130 |
Why?
|
Precancerous Conditions | 1 | 2023 | 988 | 0.130 |
Why?
|
Immunocompromised Host | 1 | 2021 | 865 | 0.130 |
Why?
|
Renal Dialysis | 1 | 2024 | 1802 | 0.120 |
Why?
|
Syphilis | 1 | 2017 | 242 | 0.120 |
Why?
|
Observer Variation | 1 | 2021 | 2622 | 0.120 |
Why?
|
Guam | 3 | 2018 | 31 | 0.110 |
Why?
|
Prenatal Care | 2 | 2018 | 1159 | 0.110 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2024 | 2964 | 0.110 |
Why?
|
Neoadjuvant Therapy | 1 | 2024 | 2896 | 0.100 |
Why?
|
Single-Cell Analysis | 1 | 2024 | 2531 | 0.100 |
Why?
|
Sexually Transmitted Diseases | 1 | 2017 | 665 | 0.090 |
Why?
|
Tumor Microenvironment | 1 | 2024 | 3939 | 0.090 |
Why?
|
Cause of Death | 1 | 2021 | 3727 | 0.090 |
Why?
|
Prenatal Diagnosis | 1 | 2017 | 1274 | 0.090 |
Why?
|
Head and Neck Neoplasms | 1 | 2024 | 2915 | 0.090 |
Why?
|
Software | 1 | 2024 | 4465 | 0.080 |
Why?
|
Health Status Disparities | 1 | 2021 | 1876 | 0.080 |
Why?
|
Middle Aged | 8 | 2024 | 223406 | 0.060 |
Why?
|
Humans | 18 | 2024 | 768369 | 0.060 |
Why?
|
Healthcare Disparities | 1 | 2021 | 3412 | 0.060 |
Why?
|
Predictive Value of Tests | 1 | 2021 | 15459 | 0.060 |
Why?
|
Skin Diseases, Genetic | 1 | 2024 | 49 | 0.060 |
Why?
|
Retrospective Studies | 5 | 2024 | 81835 | 0.050 |
Why?
|
Mutation | 2 | 2024 | 30235 | 0.050 |
Why?
|
Reproducibility of Results | 1 | 2021 | 20232 | 0.050 |
Why?
|
Mass Screening | 1 | 2017 | 5455 | 0.050 |
Why?
|
Herpesvirus 3, Human | 1 | 2022 | 159 | 0.050 |
Why?
|
Male | 6 | 2024 | 364761 | 0.050 |
Why?
|
Microphthalmia-Associated Transcription Factor | 1 | 2022 | 258 | 0.040 |
Why?
|
Exanthema | 1 | 2024 | 504 | 0.040 |
Why?
|
Immunoglobulin A | 1 | 2023 | 990 | 0.040 |
Why?
|
Risk Assessment | 1 | 2021 | 24310 | 0.040 |
Why?
|
Necrosis | 1 | 2023 | 1622 | 0.040 |
Why?
|
Time Factors | 1 | 2021 | 40271 | 0.040 |
Why?
|
Female | 9 | 2024 | 396926 | 0.040 |
Why?
|
Immunoglobulin M | 1 | 2023 | 1528 | 0.040 |
Why?
|
Endemic Diseases | 1 | 2018 | 191 | 0.040 |
Why?
|
Immunization Schedule | 1 | 2017 | 227 | 0.030 |
Why?
|
Aged | 3 | 2024 | 171514 | 0.030 |
Why?
|
Treatment Outcome | 1 | 2021 | 65408 | 0.030 |
Why?
|
Immunoglobulins | 1 | 2017 | 856 | 0.030 |
Why?
|
Neonatal Screening | 1 | 2018 | 618 | 0.030 |
Why?
|
Chlamydia Infections | 1 | 2017 | 364 | 0.030 |
Why?
|
Risk Factors | 1 | 2021 | 74915 | 0.030 |
Why?
|
Germ-Line Mutation | 1 | 2022 | 1884 | 0.030 |
Why?
|
Gonorrhea | 1 | 2017 | 346 | 0.030 |
Why?
|
United States | 1 | 2021 | 73120 | 0.030 |
Why?
|
Lymph Nodes | 1 | 2023 | 3472 | 0.020 |
Why?
|
Kidney Failure, Chronic | 1 | 2024 | 2489 | 0.020 |
Why?
|
Computational Biology | 1 | 2024 | 3549 | 0.020 |
Why?
|
Pregnancy | 3 | 2018 | 30179 | 0.020 |
Why?
|
Antibodies, Viral | 1 | 2023 | 3210 | 0.020 |
Why?
|
Immunoglobulin G | 1 | 2023 | 4570 | 0.020 |
Why?
|
Thyroid Neoplasms | 1 | 2024 | 2360 | 0.020 |
Why?
|
Cohort Studies | 2 | 2024 | 41782 | 0.020 |
Why?
|
Skin | 1 | 2023 | 4520 | 0.020 |
Why?
|
Adult | 5 | 2024 | 223528 | 0.020 |
Why?
|
Immunotherapy | 1 | 2024 | 4728 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2023 | 14725 | 0.020 |
Why?
|
Young Adult | 3 | 2018 | 60038 | 0.020 |
Why?
|
Adolescent | 3 | 2018 | 89163 | 0.020 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2023 | 9425 | 0.020 |
Why?
|
Incidence | 1 | 2023 | 21552 | 0.010 |
Why?
|
Prevalence | 1 | 2018 | 15879 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2022 | 18047 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2024 | 59679 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2018 | 26394 | 0.010 |
Why?
|
Breast Neoplasms | 1 | 2024 | 21157 | 0.010 |
Why?
|
Infant | 1 | 2017 | 36496 | 0.010 |
Why?
|
Neoplasms | 1 | 2024 | 22389 | 0.010 |
Why?
|
HIV Infections | 1 | 2017 | 17492 | 0.010 |
Why?
|
Concepts
(101)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(60)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_